The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

A study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

"We found that preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with PCa, highlighting its role in exacerbating disease progression and worsening survival.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...